Novartis AG ADR
USUSDNovartis AG ADR (SW:NOVNEE) — Drug Manufacturers - General. Numero di borse in cui sono quotate le azioni della società: 6. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.
Informazioni sull'azienda
- Sito web
- novartis.com
- Settore
- Healthcare · Drug Manufacturers - General
- Sede centrale
- BASEL, Switzerland
- Amministratore delegato
- Dr. Vasant Narasimhan M.D.
- Dipendenti
- 75 267
- Fondata
- 1996
- Azioni in circolazione
- 1.91 Mld al 2025-12-31
- Flottante
- 1.86 Mld
- Capitalizzazione di mercato
- 276.48 Mld USD
- Insider
- 0.01%
- Investitori istituzionali
- 7.27%
- Settore (SIC)
- Pharmaceutical Preparations
- Forma giuridica
- MVII
- ISIN
- CH0012005267
- LEI
- 5493007HIVTX6SY6XD66
- Payout ratio
- 71.1%
- FCF
- 15.0 Mld USD61%
- Debito
- 49.0 Mld USD2.6 anni di FCF
- Serie di dividendi
- 20 a.
Descrizione
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Borse e ticker
| Borsa | Ticker | Valuta | Prezzo | Tipo |
|---|---|---|---|---|
| US USA Stocks | NVSEF | USD | 134.22 -0.23% | azioni ordinarie |
| MI Borsa Italiana (Milan) | 1NOVN | EUR | 127.28 +1.50% | azioni ordinarie |
| SW SIX Swiss Exchange | NOVN | CHF | 119.8 -0.13% | azioni ordinarie |
| SW SIX Swiss Exchange | NOVNEE | CHF | 120.02 -1.80% | azioni ordinarie |
| VI Vienna Stock Exchange | NOVN | EUR | 126.72 | azioni ordinarie |
| XETRA Xetra | NOT | EUR | 126.82 +0.48% | azioni ordinarie |
Dividendi
Novartis AG ADR (NVSEF) paga dividendi in modo irregolare. Negli ultimi 12 mesi, sono stati pagati 3.7 CHF per azione (pagamenti: 1). In base alla storia dei pagamenti, la prossima data ex-dividendo è prevista intorno al 11.03.2027. Storia dei dividendi ininterrotta: 20 anni.
| Data ex | Pagamento | Importo | % | Tipo | Ticker |
|---|---|---|---|---|---|
| 2026-03-11 | 2026-03-12 | 3.7000 CHF | 3.3/3.3 % | annuale | US:NVSEF |
Notizie di questa settimana
Ancora nessuna notizia dal sito della società.
Principali azionisti
| Detentore | Quota | Azioni | Data del rapporto |
|---|---|---|---|
| Fisher Asset Management,… | 0.76% | 15.52 Mln | 2026-06-30 |
| Morgan Stanley | 0.43% | 8.73 Mln | 2026-06-30 |
| Dimensional Fund Advisor… | 0.4% | 8.12 Mln | 2026-06-30 |
| Primecap Management Comp… | 0.32% | 6.59 Mln | 2026-06-30 |
| LOOMIS SAYLES & CO L P | 0.26% | 5.24 Mln | 2026-06-30 |
| Bank of America Corporat… | 0.24% | 4.91 Mln | 2026-06-30 |
| VANGUARD CHESTER FUNDS-V… | 0.21% | 4.25 Mln | 2026-06-30 |
| Franklin Resources, Inc. | 0.16% | 3.25 Mln | 2026-06-30 |
| Blackrock Inc. | 0.15% | 3.05 Mln | 2026-06-30 |
| Goldman Sachs Group Inc | 0.15% | 2.98 Mln | 2026-06-30 |
| Northern Trust Corporati… | 0.14% | 2.79 Mln | 2026-06-30 |
| DFA INVESTMENT DIMENSION… | 0.11% | 2.14 Mln | 2026-04-30 |
| LOOMIS SAYLES FUNDS II-L… | 0.07% | 1.42 Mln | 2026-06-30 |
| VANGUARD HORIZON FUNDS-V… | 0.06% | 1.21 Mln | 2026-06-30 |
| Franklin Mutual Series F… | 0.06% | 1.19 Mln | 2026-06-30 |
| JANUS INVESTMENT FUND-Ja… | 0.05% | 949 726 | 2026-06-30 |
| Principal Funds, Inc-Equ… | 0.05% | 945 091 | 2026-04-30 |
| Dimensional ETF Trust-Di… | 0.04% | 888 855 | 2026-04-30 |
| Franklin Mutual Series F… | 0.04% | 812 618 | 2026-06-30 |
| Dimensional ETF Trust-Di… | 0.04% | 716 836 | 2026-04-30 |
